Table 1.
Definitions | |
---|---|
Mono-resistance | Resistance to one first-line anti-TB drug only |
Poly resistance | Resistance to more than one first-line anti-TB drug (other than both isoniazid and rifampicin) |
Multidrug resistance | Resistance to at least both Isoniazid and rifampicin |
Extensively drug resistance | Resistance to any fluoroquinolone and to at least one of the three second-line injectable drugs (capreomycin, kanamycin, and amikacin), in addition to multidrug resistance |
Rifampicin resistance | Resistance to rifampicin detected using phenotypic or genotypic methods, with or without resistance to other anti-TB drugs. It includes any resistance to rifampicin, whether mono-resistance, multidrug resistance, poly-drug resistance or extensive drug resistance |
Primary resistance | Patients may be erroneously labelled as having primary resistance if they do not disclose previous treatment for TB. |
Acquired resistance | Patients who fail treatment (and are therefore labelled to have acquired resistance) may have been infected with a resistant strain from the beginning or acquired resistance during treatment. |
TB, tuberculosis.